Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cytek Biosciences stock in Canada | $24.11

Own Cytek Biosciences shares in just a few minutes.

Cytek Biosciences is a medical devices business based in the US. Cytek Biosciences stocks (CTKB.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $23.34 – a decrease of 7.13% over the previous week. Cytek Biosciences employs 429 staff and has a trailing 12-month revenue of around $110.4 million.

How to buy Cytek Biosciences stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: CTKB in this case.
  5. Research Cytek Biosciences stocks. The platform should provide the latest information available.
  6. Buy your Cytek Biosciences stocks. It's that simple.

Is it a good time to buy Cytek Biosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cytek Biosciences stock price

Use our graph to track the performance of CTKB stocks over time.

Cytek Biosciences stocks at a glance

Information last updated 2021-09-20.
Latest market close$24.11
52-week range$17 - $28.7
50-day moving average $24.1671
200-day moving average $23.493
Wall St. target price$27
PE ratio 475.8182
Dividend yield N/A (0%)
Earnings per share (TTM) $0.055

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
BMO InvestorLine
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$9.95 + $1.25 per options contract
$0 if conditions met, otherwise $25/quarter
$0 - $9.95
Buy and sell a select group of Canada’s most popular ETFs without paying commissions.
An easy-to-use online trading platform with access to research, tools, and the option to access InvestorLine adviceDirect for additional professional support.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Cytek Biosciences price performance over time

Historical closes compared with the last close of $24.11

1 week (2021-09-17) -7.13%
1 month (2021-08-25) 6.21%

Is Cytek Biosciences under- or over-valued?

Valuing Cytek Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cytek Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Cytek Biosciences's P/E ratio

Cytek Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 476x. In other words, Cytek Biosciences stocks trade at around 476x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stocks or simply that they're over-valued.

However, Cytek Biosciences's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.

    Cytek Biosciences's EBITDA

    Cytek Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$20.2 million.

    The EBITDA is a measure of a Cytek Biosciences's overall financial performance and is widely used to measure a its profitability.

    To put Cytek Biosciences's EBITDA into context you can compare it against that of similar companies.

    Cytek Biosciences financials

    Revenue TTM USD$110.4 million
    Operating margin TTM 17.69%
    Gross profit TTM USD$51.7 million
    Return on assets TTM 0%
    Return on equity TTM 0%
    Profit margin 13.51%
    Book value N/A
    Market capitalisation USD$3.5 billion

    TTM: trailing 12 months

    How to short and sell Cytek Biosciences stocks

    1. Create a CFD or spread betting account.
    2. Search for the stock code. E.g. "CTKB.US"
    3. Choose your position size.
    4. Select "sell" rather than "buy".
    5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

    There are currently 44,741 Cytek Biosciences stocks held short by investors – that's known as Cytek Biosciences's "short interest". This figure is 51.1% down from 91,557 last month.

    There are a few different ways that this level of interest in shorting Cytek Biosciences stocks can be evaluated.

    Cytek Biosciences's "short interest ratio" (SIR)

    Cytek Biosciences's "short interest ratio" (SIR) is the quantity of Cytek Biosciences stocks currently shorted divided by the average quantity of Cytek Biosciences stocks traded daily (recently around 248561.11111111). Cytek Biosciences's SIR currently stands at 0.18. In other words for every 100,000 Cytek Biosciences stocks traded daily on the market, roughly 180 stocks are currently held short.

    To gain some more context, you can compare Cytek Biosciences's short interest ratio against those of similar companies.

    However Cytek Biosciences's short interest can also be evaluated against the total number of Cytek Biosciences stocks, or, against the total number of tradable Cytek Biosciences stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cytek Biosciences's short interest could be expressed as 0% of the outstanding stocks (for every 100,000 Cytek Biosciences stocks in existence, roughly 0 stocks are currently held short) or 0.0016% of the tradable stocks (for every 100,000 tradable Cytek Biosciences stocks, roughly 2 stocks are currently held short).

    Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Cytek Biosciences.

    Find out more about how you can short Cytek Biosciences stock.

    Cytek Biosciences stock dividends

    We're not expecting Cytek Biosciences to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

    Cytek Biosciences overview

    Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Its customers include pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. Cytek Biosciences, Inc. was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. The company was incorporated in 2014 and is headquartered in Fremont, California.

    Frequently asked questions

    Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

    More on investing

    More guides on Finder

    Ask an Expert

    You must be logged in to post a comment.

    Go to site